Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
Roche announced this morning that Avastin, the blockbuster cancer drug that was a driving force in its acquisition of biotech stalwart Genentech, failed to prevent colon tumors from returning in a large clinical trial. Details on the study are scant. Full results will be presented at the annual meeting of the American Society of Clinical Oncology in May.
